Tin tức & Cập nhật
Xem bài viết Gan
Xem
Chỉ hiển thị Multimedia

Which factors predict mortality in advanced HCC?
01 Mar 2024
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
01 Mar 2024

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024
bởiAudrey Abella
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
13 Feb 2024






